Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation

Proteasome inhibitors can resensitize cells that are resistant to tumors necrosis factor-related apoptotic-inducing ligand (TRAIL)-mediated apoptosis. However, the underlying mechanisms of this effect are unclear. To characterize the mechanisms of interaction between proteasome inhibitors and TRAIL protein, we evaluated the effects of combined treatment with the proteasome inhibitors bortezomib and MG132 and TRAIL protein on two TRAIL-resistant human colon cancer cell lines, DLD1-TRAIL/R and LOVO-TRAIL/R. Both bortezomib and MG132 in combination with TRAIL enhanced apoptotosis induction in these cells, as evidenced by enhanced cleavage of caspases 8, 9, and 3, Bid, poly (ADP-ribose) polymerase and by the release of cytochrome C and Smac. Subsequent studies showed that combined treatment with bortezomib or MG132 resulted in an increase of death receptor (DR) 5 and Bik at protein levels but had no effects on protein levels of DR4, Bax, Bak, Bcl-2, Bcl-XL, or Flice-inhibitory protein (FLIP). Moreover, c-Jun N-terminal kinase (JNK) is activated by these proteasome inhibitors. Blocking JNK activation with the JNK inhibitor SP600125 attenuated DR5 increase, but enhancement of apoptosis induction and increase of Bik protein were not affected. However, bortezomib-mediated TRAIL sensitization was partially blocked by using siRNA to knockdown Bik. Thus, our data suggests that accumulation of Bik may be critical for proteasome inhibitor-mediated re-sensitization of TRAIL.

[1]  Wei Guo,et al.  Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors , 2005, Oncogene.

[2]  P. Chiao,et al.  Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  W. Greene,et al.  Shaping the nuclear action of NF-κB , 2004, Nature Reviews Molecular Cell Biology.

[4]  Qin He,et al.  Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells , 2004, Oncogene.

[5]  K. Coser,et al.  The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Gu,et al.  Induction of Apoptosis and Down-Regulation of Bcl-XL in Cancer Cells by a Novel Small Molecule, 2[ [3-(2,3-Dichlorophenoxy)propyl]amino]ethanol , 2004, Cancer Research.

[7]  E. Henson,et al.  Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFκB activation in epithelial derived cell lines , 2002, Apoptosis.

[8]  W. Greene,et al.  Shaping the nuclear action of NF-kappaB. , 2004, Nature reviews. Molecular cell biology.

[9]  S. Grant,et al.  Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process , 2003, Oncogene.

[10]  W. Zong,et al.  The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells , 2003, Oncogene.

[11]  B. Dörken,et al.  Induction of cell death by the BH3‐only Bcl‐2 homolog Nbk/Bik is mediated by an entirely Bax‐dependent mitochondrial pathway , 2003, The EMBO journal.

[12]  P. Elliott,et al.  The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. , 2003, Blood.

[13]  H. Lenz.  Clinical update: proteasome inhibitors in solid tumors. , 2003, Cancer treatment reviews.

[14]  J. Adams,et al.  Proteasome inhibitors as new anticancer drugs , 2002, Current opinion in oncology.

[15]  H. Wajant,et al.  Selective Inhibition of FLICE-like Inhibitory Protein (FLIP) Expression With Small Interfering RNA Oligonucleotides (siRNAs) Is Sufficient to Sensitize Tumor Cells for TRAIL-Induced Apoptosis , 2002 .

[16]  J. Gu,et al.  Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line , 2002, Gene Therapy.

[17]  J. Adams.  Development of the proteasome inhibitor PS-341. , 2002, The oncologist.

[18]  H. Wajant,et al.  Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. , 2002, Molecular medicine.

[19]  David W. Anderson,et al.  SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Hersey,et al.  The Role of NF-κB in TNF-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis of Melanoma Cells1 , 2001, The Journal of Immunology.

[21]  R. Ho,et al.  Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. , 2001, Cancer research.

[22]  D. Dicker,et al.  Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. , 2001, International journal of oncology.

[23]  A. Strasser,et al.  BH3-Only Proteins—Essential Initiators of Apoptotic Cell Death , 2000, Cell.

[24]  K. Shiraki,et al.  Chemotherapeutic Agents Augment TRAIL‐Induced Apoptosis in Human Hepatocellular Carcinoma Cell Lines , 2000, Hepatology.

[25]  J. Tschopp,et al.  Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. , 2000, Cancer research.

[26]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[27]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[28]  I. Herr,et al.  Inhibition of Nuclear Factor κB Activation Attenuates Apoptosis Resistance in Lymphoid Cells , 1998 .

[29]  Keiji Tanaka,et al.  Transcriptional squelching by ectopic expression of E2F-1 and p53 is alleviated by proteasome inhibitors MG-132 and lactacystin , 1997, Oncogene.